Purpose: Caffeine, a nonselective antagonist of adenosine receptors, is the most popular psychostimulant worldwide. Recently, a protective role of moderate chronic caffeine consumption against neurodegenerative diseases such as Alzheimer's and Parkinson's disease has been discussed. Thus, aim of the present study was an in vivo investigation of effects of longterm caffeine consumption on the adenosine A 1 receptor (A 1 AR) in the rat brain. Procedures: Sixteen adult, male rats underwent five positron emission tomography (PET) scans with the highly selective A 1 AR radioligand [
Introduction
Adenosine is involved in numerous physiological as well as pathophysiological processes and acts as a neuromodulator on all four G protein-coupled receptors (A 1 , A 2A , A 2B , A 3 ) [1] . The A 1 adenosine receptor (A 1 AR) has the widest distribution and highest density in the brains of rats [2] and humans [3] . Its primary role in processes like sleep-wake regulation, memory consolidation, epilepsy, and schizophrenia (for review see [4, 5] ) induced great interest in in vivo imaging techniques for the A 1 AR with positron emission tomography (PET) in order to visualize molecular processes. The flourine-18-labeled A 1 AR antagonist 8-cyclopentyl-3-(3-[
18 F]fluoropropyl)-1-propylxanthine ([ 18 F]CPFPX, [6] ) has been well characterized as a highly selective A 1 AR radioligand in rats [7] and humans [8] .
The best-known and frequently consumed adenosine antagonist is caffeine which acts on A 1 and A 2A adenosine receptor subtypes in a nearly equipotent manner [9] . Caffeine reduces sleepiness [10] and increases cognitive performance and attention [11, 12] . Moreover, epidemiological studies showed that caffeine has a protective role against neurodegenerative diseases such as Alzheimer's and Parkinson's disease [13, 14] . Although the beneficial mode of action of chronic caffeine consumption remains hypothetical, an involvement of adenosine and its neuromodulatory properties seems to be most likely. During pathophysiological conditions such as hypoxia and cerebral ischemia, endogenous adenosine is released and subsequently reduces the neuronal damage in tissue primarily mediated via the ubiquitous A 1 AR (for review see [15] ). Thereby, the caffeine-induced receptor blockade, leading to an increase in adenosine concentration (own unpublished data), may finally contribute to the neuroprotective effects of chronic caffeine consumption. In the past, the molecular effects of chronic oral caffeine consumption on the A 1 AR were investigated in various studies with inconsistent results. Several studies revealed an upregulation [16] [17] [18] , while other studies reported constant A 1 AR density [19] [20] [21] after chronic caffeine administration up to 42 days. However, Marangos et al. [22] and Boulenger et al. [23] already showed that the impact of chronic caffeine ingestion on the A 1 AR expression was dependent on the duration of caffeine intake and dosage, respectively. All these studies were conducted exclusively in vitro and mainly with agonists as radioligands.
The aim of the present study was to examine the regional effects of long-term caffeine consumption on A 1 ARs in vivo with PET and the highly affine and selective radioligand [ 18 F]CPFPX. After determination of baseline A 1 AR availability, caffeine (30 mg/kg/day) was administered in drinking water over an application period of 84 days which substantially exceeds previous studies. In human life time, this time span corresponds to approximately 8 years [24] and reflects the chronic consumption behavior of humans adequately.
Since caffeine and the applied radioligand both act on the A 1 AR [25] , caffeine was withdrawn before PET scanning in order to ensure a valid quantification of the A 1 AR. PET measurements were performed on day 1, 2, 4, and 7 of caffeine withdrawal (caffeine-treated group) or normal aging (control group). Previous studies showed that the observed effects of chronic caffeine consumption on the A 1 AR persisted at least 2 days after caffeine withdrawal [16, 26] . Consequently, the first PET measurement after caffeine withdrawal (day 1) likely reflects the receptor availability during chronic caffeine application. However, Boulenger, et al. [16] investigated the effects of caffeine withdrawal with a radioligand unspecific for A 1 ARs and A 2A ARs. Thus, it is not clear whether the observed relatively long-lasting (15 days) increase in receptor availability is due to radioligand binding to A 1 ARs or A 2A ARs.
In contrast, Kaplan, et al. [26] showed a return to baseline A 1 AR availabilities after 4 days measured ex vivo with an A 1 AR specific radioligand. However, in the respective study, the total and non-specific binding of the radioligand was not determined in the same but in different animals, and specific binding was calculated by total minus mean nonspecific binding. As the uptake of the radioligand might individually vary, values are likely to be more variable than in neuroreceptor quantification with in vivo PET providing estimates of total and non-specific binding within the same animal.
In this regard, the hypothesis of an A 1 AR upregulation that may trigger the neuroprotective effects of chronic caffeine consumption is examined in vivo for the first time.
Materials and Methods

Animals and Study Design
Experiments were performed in 16 adult, male SpragueDawley rats (age 3-4 months, 9 400 g, Charles River Laboratories) housed in pairs in a 12-h light/dark cycle (lights on 7:00 a.m. to 7:00 p.m.) at 22 ± 1°C with access to food and water ad libitum. After at least one week of acclimatization, baseline A 1 AR availability was determined with PET. Afterwards, rats were assigned to two experimental groups: Caffeine-treated rats (n = 8, mean weight at baseline PET 451 ± 34 g) received caffeinated (30 mg/kg bodyweight/day, Sigma-Aldrich, St. Louis, MO) tap water ad libitum for 12 weeks (Fig. 1) . Caffeine intake of each pair was weekly determined based on the average bodyweight and fluid intake. After 12 weeks of chronic caffeine administration, repeated A 1 AR PET measurements were performed on day 1 (after 4.4 h), day 2 (after 27.8 h), day 4 (after 75.8 h), and day 7 (after 172.0 h) of caffeine withdrawal at the same time of day (~6 h after lights on) in order to control for potential circadian effects. Control rats (n = 8, mean weight at baseline PET: 458 ± 16 g) receiving pure tap water were housed under the same conditions and were analyzed with an identical time schedule. All Nabbi-Schroeter D. et al.: Effects of Caffeine Intake on A 1 ARexperiments were approved by the regional authorities and conducted in accordance with the German Animal Protection Act.
PET Imaging and Image Analysis
PET acquisition as well as image analysis were performed as previously described by Kroll et al. [27] .
Animals were scanned in pairs head to head in prone position with a Siemens Inveon multimodality PET scanner (Siemens, Knoxville, TN, USA) under isoflurane anesthesia (1.5-2% isoflurane in 2 l O 2 /min) guided by a respiratory sequence of~50/min. Body temperature (rectal probe) and respiratory sequence were monitored (BioVet System, m2m Imaging, Salisbury, QLD, Australia) and kept in physiological ranges. For attenuation correction, a 15-min transmission measurement was performed with a dual Co-57 source prior to emission scans. Subsequently, a bolus of the inhouse synthesized [ 18 F]CPFPX [6] diluted in 1ml NaCl was constantly administered over 1 min with a syringe pump (model 44, Harvard Apparatus, Holliston, MA, USA) via a tail vein catheter.
Emission scans were started simultaneously to the tracer application for the first animal. For the second animal, tracer administration started with a time lag of 3 min. For mean injected radioactivity and injected amount of substance per scan and group, see Table 1 . List mode data were collected for 75 min, and data of 70 min (beginning with the radioligand application) were sorted separately for each animal in a dynamic sequence of 12 × 10-s, 3 × 20-s, 3 × 30-s, 3 × 1-min, 3 × 2.5-min, and 11 × 5-min frames. Dynamic PET data were reconstructed per time frame by filtered back projection after Fourier rebinning into 2D sinograms. The corresponding voxel size was 0.7764 × 0.7764 × 0.796 m 3 . Data were corrected for random coincidences, scatter radiation, and attenuation.
Individual integrated PET images were manually scaled and co-registered to the slightly modified rat brain atlas implemented in PMOD (version 3.408, PMOD Group, Zürich, Switzerland). After inspection of dynamic data for potential head movements, the co-registration transformation matrix was applied to all frames. Subsequently, all baseline (BL) images were automatically adjusted (PMOD algorithm Bmouse changing^) to a matched average PET template based on 13 [ 18 F]CPFPX PET datasets of Sprague-Dawley rats with corresponding weight. Manually co-registered PET data of the remaining four PET scans were finally registered to the automatically co-registered BL images applying the same algorithm in order to minimize the bias introduced by variable manual co-registrations to the rat brain template. After visual inspection of exact covering of anatomical structures, time-activity curves (TACs) were defined based on the rat brain atlas for the following regions: the cortex (0.51 ml), cerebellum (0.15 ml), caudatus putamen (0.09 ml), hippocampus (0.07 ml), thalamus (0.06 ml), hypothalamus (0.04 ml), nucleus accumbens (0.02 ml), and olfactory bulb (0.05 ml). For quantitative analysis of A 1 AR availabilities, the binding potential (BP ND ), a parameter directly proportional to the maximum number of available receptors [28] , was estimated via the simplified reference tissue model (SRTM) [29] on the basis of the olfactory bulb as a reference region. The parametric BP ND images (n = 8 per group) were generated with SRTM2 and fixed k 2 ' values being calculated by averaging k 2 ' parameters of high-binding regions from SRTM.
Statistics
All values are displayed as mean ± standard deviation (SD). Results were generated by calculating the following parameters: *100% b ) c a l c u l a t e d x a n t h i n e p l a s m a l e v e l = initial plasma level μM ½ Âe
−ln2Â
decaffeinated period h ½ half −life h ½ Fluid intake and weight gain of caffeine-treated and control animals during the period of chronic caffeine administration were compared with two-tailed t tests. General parameters of the scan sessions (length of anesthesia, injected activity, and injected amount of substance) were analyzed with a univariate analysis of variance (ANOVA). Differences in A 1 AR availability between the caffeinetreated and control group were determined by a mixed model ANOVA (rmANOVA) with condition as betweensubject factor and the different brain regions and scan session treated as within-subject factors. Significant results (p G 0.05) were further evaluated by post hoc two-tailed t tests (independent or matched as appropriate) and subsequent Bonferroni correction. All statistical calculations were performed with the SPSS software (version 22, SPSS Inc., Chicago, IL).
Results
During the administration period (caffeine or tap water, respectively) of 12 weeks, there were no significant differences in weight gain and daily water intake between the caffeine-treated and the control group ( Table 2 ). The mean caffeine intake was 29.4 ± 1.4 mg/kg bodyweight/day and remained stable over the entire application period. Scan parameters such as length of anesthesia at scan start as well as injected dose were not significantly different between the scans both within and between the groups, whereas the injected amount of substance between scans showed significant differences within the control group (Table 1 , p = 0.006). However, differences did not withstand subsequent post hoc analysis via unpaired t tests followed by Bonferroni adjustment with a threshold of p G 0.005. Figure 2 shows mean parametric images of the caffeinetreated and control animals at different time-points reflecting the A 1 AR availability in the rat brain. In general, high A 1 AR densities were observed in the cerebellum, hippocampus, thalamus, and cortex. In contrast, the nucleus accumbens and hypothalamus showed low A 1 AR availabilities. Corresponding whole brain BP ND data for both groups and all investigated time-points are depicted in Fig. 3 . Directly after caffeine discontinuation on day 1 (4.4 h after withdrawal), whole brain A 1 AR availability was significantly reduced by −34.5% (p G 0.001) in caffeine-treated animals compared to the controls. Regional analysis displayed reductions in A 1 AR availability between 31.3% (hypothalamus) and 37.3% (cerebellum). After a caffeine discontinuation of approximately 27 h (day 2), these group-specific effects were abolished in all investigated regions, and A 1 AR availability in caffeine-treated animals settled around baseline values.
Analysis of data with a mixed model ANOVA indicated significant interactions for all parameters (Bregion x scan x group^, F (7.94) = 4.4, p G 0.001) as well as for each individual combination (Bregion x scan^, F (7.94) = 4.2, p = 0.001; Bregion x group^, F (3.44) = 3.8, p = 0.016; Bscan x group^, F (3.45) = 9.3, p G 0.001). Post hoc analysis revealed stable BP ND values for all time-points in control animals (Fig. 3) . In contrast, in caffeine-treated animals, post hoc analysis indicated significant differences between baseline and day 1 of caffeine withdrawal in regions with high A 1 AR availabilities such as cerebellum and thalamus (33.5 ± 12.5% for cerebellum; 27.5 ± 11.9% for thalamus, p G 0.001, Fig. 4 ). In regions with low A 1 AR availabilities like hypothalamus and nucleus accumbens, these differences could not be observed.
Discussion
The present in vivo study examined the long-term effects of chronic caffeine administration on A 1 AR availability using [ 18 F]CPFPX and small animal PET. Epidemiological studies [13, 14] . Thus, a dose of 3-5 cups of coffee per day reduced the risk of Alzheimer's disease up to 65%. The caffeine dose in the present study was chosen based on intake doses of these epidemiological studies in order to elucidate the neuroprotective molecular mechanisms of caffeine. Considering the faster metabolism of rodents [30] , the caffeine intake in the present study corresponded to a human consumption of 4-5 cups of coffee per day (400-500 mg caffeine) thus representing a common daily caffeine intake in industrialized countries [9] . In the present study, we did not find a long-persistent upregulation of functionally available A 1 ARs in vivo as after 27 h of caffeine withdrawal A 1 AR availability settled around baseline values in chronically caffeine-treated animals. At this time-point, the remaining xanthine level is negligible (G 0.25%, see below) and any interference at the A 1 AR with the radioligand is unlikely. Nevertheless, our results are contradictory to some previous in vitro studies showing a persistent upregulation of the A 1 AR after short-term caffeine withdrawal [16, 26, 31] . However, in these studies, shorter time intervals and much higher dosages of caffeine as well as partly rather unphysiological application routes were chosen. Thus, conditions of normal daily caffeine intake in humans were not ideally reflected. Moreover, in all studies, homogenates, representing the whole amount of receptors in a certain brain region, were investigated instead of the functionally available portions of receptors. Finally, agonists [31] , detecting changes in affinity states of the A 1 AR, or relatively unspecific A 1 AR/A 2A R antagonists [16] were used which might further explain inconsistent results. Interestingly, Kaplan, et al. [26] showed a return to baseline A 1 AR availability after high-dosage caffeine administration and subsequent 4 days of withdrawal by using the highly specific A 1 AR antagonist [ 3 H]DPCPX which is structurally closely related to the currently used radioligand [
18 F]CPFPX. These findings further suggest that incongruent results might be due to higher dosages of caffeine administered and the use of different radioligands.
Directly after caffeine discontinuation (4.4 h of withdrawal), we observed a significant decrease in A 1 AR availability which is contradictory to previous reports. In the past, either an upregulation [16] [17] [18] or constant levels [19] [20] [21] decrease in A 1 AR availability. As caffeine concentrations in plasma were not determined in this study, the caffeine plasma level was estimated based on similarly treated animals. The plasma caffeine concentration in these animals was 7.29 ± 1.41 μg/ml (37.54 μM) 4-6 h before the first withdrawal scan (day 1). Estimation of the residual plasma levels were performed [32] considering the dose-dependent half-life t ½ of caffeine (1-4 h) [32] [33] [34] [35] and the decaffeinated period (4-6 h). Calculated plasma concentration on day 1 of caffeine withdrawal was between 4.18 μM (6 h decaffeinated, t ½ = 1 h) and 18.77 μM (4 h decaffeinated, t ½ = 4 h). These plasma concentrations corresponded to an estimated receptor blockade between 4 and 11% [36] . Consequently, the highly reduced [ 18 F]CPFPX binding on day 1 after caffeine withdrawal is unlikely attributable to remaining caffeine.
However, a blockade of A 1 ARs can also be caused by the metabolites of caffeine. In rodents, the main pharmacologically active caffeine metabolites are theophylline, paraxanthine, and theobromine with ratios of caffeine to its metabolites of 1:1.5 for theophylline, 1:1.25 for paraxanthine, and 1:3 for theobromine [37] . Accordingly, the calculated plasma concentrations of caffeine metabolites were 11.21 μM for theophylline, 9.04 μM for paraxanthine, and 21.24 μM for theobromine 4-6 h before the first withdrawal scan. In contrast to caffeine, the plasma concentration of its metabolites is not equal to the concentration in the cerebrospinal fluid. Thus, a correction factor of 0.7 for theophylline and 1.3 for theobromine was considered [38] . For paraxanthine no correction factor has been determined yet, therefore the corresponding residual concentrations might be slightly biased. Regarding caffeine metabolites' half-lives [32] and their specific binding to the A 1 AR [36] , minimum binding on the A 1 AR (6 h decaffeinated) was 38% by theophylline, 7% by paraxanthine (uncorrected), and 3% by theobromine. Consequently, the reduced [
18 F]CPFPX binding (−34.5%) observed in the first scan after caffeine withdrawal is presumably due to a remaining A 1 AR blockade by the metabolites of caffeine, especially by theophylline.
Hence, at early time-points after withdrawal residual xanthine concentration would disguise potential short-term caffeine-induced molecular effects on the A 1 AR. However, most likely reduced BP ND values on day 1 reflects masked baseline values and no short-term upregulation, since previous studies showed A 1 AR changes of about 15-35% [16] [17] [18] . Thus, such an upregulation would result in baseline values under conditions of residual xanthine binding.
In the past, a divergent response of various regions on caffeine was described by Hawkins, et al. [39] and Marangos, et al. [22] which is in line with the current results showing divergent responses to caffeine treatment and subsequent withdrawal in the nucleus accumbens and hypothalamus. Potentially in these regions, chronic caffeine administration leads to a lower receptor occupation or to a faster unblocking of receptors after caffeine withdrawal. However, both regions are of small size and showed low tracer accumulation resulting in low signal-to-noise ratios. Accordingly, quantification of A 1 AR availability might be slightly biased although stable test-retest results could be generated [27] .
This study was performed with the radioligand [ 18 F]CPFPX showing a high affinity [6] and selectivity for the A 1 AR [7] . Moreover, neither weight, daily water intake nor the scan parameters were significantly different between both groups. Exclusively, the injected amount of substance showed a trend towards significance in the control group notwithstanding post hoc analysis. Nevertheless, the injected amount of substance corresponded in both groups and at each scan to a negligible receptor blockade of G 5% [7] according to the tracer principle making an influence on A 1 AR quantification unlikely. For the determination of the outcome parameter (BP ND ) via SRTM, the olfactory bulb does not represent an ideal reference region, since it displays a specific binding of~45% [7] . However, the non-invasive quantification of A 1 AR densities with the olfactory bulb as a reference region was shown to be reliable and highly correlated with parameters determined with an arterial input function [7, 27] . Nevertheless, it should be kept in mind that the reference region might be affected by the application of caffeine, thus differences in BP ND might be under-or overestimated. As effects of caffeine application on specific radioligand binding in the reference region cannot be directly estimated in the current study, we assessed the impact of changes by values obtained in a previous study [7] as well as tissue activity concentrations both in a region with high specific [ 18 F]CPFPX binding and the reference region. Previous data [7] showed a V T of 0.65 ml/cm 3 in the olfactory bulb derived from a metabolite corrected plasma input function and modeling via the two-tissue compartment model. In comparison, V T in high-binding regions like the thalamus was 1.85 ml/cm 3 . To estimate the impact of chronic caffeine consumption in the reference region, we tried to calculate the influence on the outcome parameter BP ND with the above-mentioned values. The BP ND is defined as:
For a reference region not void of specific binding, this formula can be rearranged to:
By filling in the concrete values, BP ND can be estimated to be 1.85 in the thalamus. In case of a reference region with certain amounts of specific binding (V S ), this portion will change in the target region as well as in the reference region under the situation of a competition at the receptor level. For a blockade of e.g., 50%, this will result in a BP ND = 1.1.
Accordingly, extent of receptor blockade by caffeine is not completely mirrored by BP ND as this outcome parameter is less affected and might even slightly underestimate the situation. This is in line with our estimation of the impact of possible changes in the reference region olfactory bulb by tissue activity concentrations and previous simulation in humans. Uptake of radioligand into tissue both in a region with high specific [ 18 F]CPFPX binding (thalamus) and the reference region showed that chronic caffeine application led to the following changes in TACs:~−28% in the reference region and~−52% in the thalamus resulting in an estimated net change of~−20% specific binding in the thalamus.
Simulations in humans showed that such a change resulted in a change of BP ND of~−15% when equal variations in the target and reference region are assumed [40] . This again implies that the presented decrease of BP ND in the first withdrawal scan of the current study might be slightly underestimated by approximately 5%.
Nevertheless, this relatively little methodological bias does not change overall results of the study despite the region-specific intraindividual changes in the low-binding regions hypothalamus and nucleus accumbens which became significant when data were exploratory corrected for the calculated underestimation. However, as already discussed above these regions has to be regarded with caution due to low-binding and relatively high noise.
Conclusion
This study provides first in vivo evidence that there is no long-persistent upregulation of functional A 1 AR expression after chronic caffeine treatment. Transient decreases in A 1 AR availability directly after caffeine withdrawal observed in the current study were most likely caused by an A 1 AR occupation by residual amounts of caffeine metabolites masking an unchanged A 1 AR expression at this early time-point. Altogether, current data excludes a longpersistent upregulation of functional A 1 AR availability as the molecular basis for the neuroprotective effects of caffeine. Nevertheless, it cannot be excluded that the adenosinergic system with its neuromodulatory properties is involved in the neuroprotective effects of caffeine maybe as proposed by Green, et al. [41] via changes in affinity states of A 1 ARs.
